Akebia Therapeutics AKBA

$0.74 -0.02 (-2.93%)

Valuation

Market cap
211,875,000
Revenue TTM
$236,200,000
Net income TTM
$-5,350,000
PE ratio
0.00
Forward PE
—
Profit margin
-2.27%
Debt to equity
1.98

Trading

Volume
5,027,300
Avg volume
8,436,014
Day's range
$0.74 – $0.80
Shares out
277,106,000
Stochastic %K
78%
Beta
0.18
Analysts
Strong Sell
Price target
$3.92

Price

Company profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric cit...

Show more

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
617 871 2098
Website
https://www.akebia.com
Address
180 Third Avenue, Floor 2, Waltham, United States

Latest news

Stocktwits

Mr_Pithy Oct 30, 4:33 PM
$AKBA AKEBIA’S 2026 YEAR END CATALYSTS - (1)Q3 double beat on Wall St. consensus & guidance; (2)Kidney Care Access Protection Act passage; (3)CMS’ TDAPA extension; (4)Positive Davita patient numbers on village wide rollout; (5)VOCAL trial results mirror VOICE results. Good luck 🍀 to all of our honest investors.
1 replies
BuyAndHoldStocks Oct 30, 3:32 PM
$AKBA
0 replies
Jeko44 Oct 30, 3:04 PM
$AKBA this pretty much sums up this board…
1 replies
Walleye001 Oct 30, 2:37 PM
$AKBA
0 replies
paivante69 Oct 30, 2:26 PM
$AKBA estamos com um grave problema A gestora será obrigada a vender as posições detidas em ETFs e fundos de índice indexados ao Russell 2000, sendo o caso mais notório o iShares Russell 2000 ETF (IWM). Se a AKBA sair do índice, o mandato legal desse fundo específico exige a liquidação total da posição para acompanhar a nova carteira oficial.
1 replies
asavasir Oct 30, 2:12 PM
$AKBA will be over 82 today when market reverses in the afternoon for the month end
2 replies
ROCKET123 Oct 30, 2:01 PM
$AKBA Looking to become Standard of Care while struggling to reach compliance and reach a dollar…Also kicked out of Russell index…Lots to be proud off…
0 replies
Bidzill Oct 30, 1:56 PM
$AKBA Update from yesterday's illustration of a short and long trend convergence:
1 replies